search

Active clinical trials for "Endometrial Neoplasms"

Results 451-460 of 990

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu...

Advanced Adult Primary Liver CancerAnaplastic Thyroid Cancer125 more

Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy

Completed26 enrollment criteria

Macrobiotic Diet and Flax Seed: Effects on Estrogens, Phytoestrogens, & Fibrinolytic Factors

Cardiovascular DiseasesOsteoporosis2 more

This study will assess whether alternative, high phytoestrogen dietary interventions result in favorable effects on biological parameters that have been associated with hormone-dependent cancers, cardiovascular disease, and osteoporosis.

Completed3 enrollment criteria

Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma

Endometrial CancerKidney Cancer3 more

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether giving chemotherapy after surgery is more effective than surgery alone in treating soft tissue sarcoma. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without chemotherapy in treating patients who have soft tissue sarcoma.

Completed65 enrollment criteria

Dendritic Cells for Immunotherapy of Metastatic Endometrial Cancer Patients

Endometrial Cancer

Prevention of infectious diseases through immunization is one of the greatest achievements of modern medicine. Nonetheless, considerable challenges remain for improving the efficacy of existing vaccines for therapeutic immunizations for diseases such as cancer. The investigators were amongst the first groups worldwide that introduced tumor antigen-loaded dendritic cell (DC)-based vaccines in the clinic1-3. Effective immune responses and favorable clinical outcomes have indeed been observed4-7. Thus far, mainly conventional in vitro generated monocyte-derived DCs (moDC) have been used in clinical trials worldwide. In the past 14 years the investigators have treated more than 375 patients and proven that DC therapy is feasible and non-toxic. The investigators observed that long lasting tumor specific T cell-mediated immunological responses are clearly linked to increased progression free survival as well as overall survival8. In conclusion, based on all these observations the investigators are convinced that pDC and myDC employ different, and probably more optimal mechanisms to combat cancer. In addition, based on in vitro data and preclinical studies that suggest that blood pDC and myDC act synergistically, the investigators hypothesize that the combination of myDC and pDC may induce stronger anti-tumor immune responses as compared to pDC or myDC alone, or moDC.

Completed32 enrollment criteria

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

Endometrial CancerEndometrial Carcinosarcoma4 more

This study will test the safety and efficacy of the experimental drug called durvalumab with or without another experimental drug called tremelimumab in endometrial cancer. Radiologic tumor assessment will be repeated every 8 weeks +/- 7 days for the first 48 weeks and then every 12 weeks +/- 7 days until PD. For patients who remain progression free 2 years post completion of protocol directed treatment, every 6 months +/- 1 month. irRECIST assessments will only be completed for patients continuing treatment beyond PD.

Completed51 enrollment criteria

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Biliary Tract Cancer (BTC)Colorectal Cancer (CRC)4 more

The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.

Completed16 enrollment criteria

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Ovary CancerCervix Cancer7 more

The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.

Completed25 enrollment criteria

FPA150 in Patients With Advanced Solid Tumors

Breast CancerOvarian Cancer2 more

This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1 antibody in patients with advanced solid tumors. The Phase 1a, open-label, cohort will identify a recommended dose of FPA150 to use for Phase 1a Combination (FPA150 and Pembrolizumab) Safety Lead-in and for Phase 1b monotherapy cohorts.

Completed59 enrollment criteria

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Ovary CancerCervix Cancer5 more

The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.

Completed54 enrollment criteria

A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of...

Endometrial Neoplasms

The primary purpose of this study is to determine if sapanisertib in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.

Completed50 enrollment criteria
1...454647...99

Need Help? Contact our team!


We'll reach out to this number within 24 hrs